Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Neuroendocrine tumours: the role of imaging for diagnosis and therapy.

van Essen M, Sundin A, Krenning EP, Kwekkeboom DJ.

Nat Rev Endocrinol. 2014 Feb;10(2):102-14. doi: 10.1038/nrendo.2013.246. Epub 2013 Dec 10. Review.

PMID:
24322649
2.

Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours.

Sundin A.

Best Pract Res Clin Gastroenterol. 2012 Dec;26(6):803-18. doi: 10.1016/j.bpg.2012.12.004. Review.

PMID:
23582920
3.

Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.

Sadowski SM, Neychev V, Millo C, Shih J, Nilubol N, Herscovitch P, Pacak K, Marx SJ, Kebebew E.

J Clin Oncol. 2016 Feb 20;34(6):588-96. doi: 10.1200/JCO.2015.64.0987. Epub 2015 Dec 28.

4.

Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors.

Toumpanakis C, Kim MK, Rinke A, Bergestuen DS, Thirlwell C, Khan MS, Salazar R, Oberg K.

Neuroendocrinology. 2014;99(2):63-74. doi: 10.1159/000358727. Epub 2014 Jan 21. Review.

5.

Comparison of diagnostic accuracy of (111)In-pentetreotide SPECT and (68)Ga-DOTATOC PET/CT: A lesion-by-lesion analysis in patients with metastatic neuroendocrine tumours.

Van Binnebeek S, Vanbilloen B, Baete K, Terwinghe C, Koole M, Mottaghy FM, Clement PM, Mortelmans L, Bogaerts K, Haustermans K, Nackaerts K, Van Cutsem E, Verslype C, Verbruggen A, Deroose CM.

Eur Radiol. 2016 Mar;26(3):900-9. doi: 10.1007/s00330-015-3882-1. Epub 2015 Jul 12.

PMID:
26162577
6.

Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.

Hicks RJ.

Cancer Imaging. 2010 Oct 4;10 Spec no A:S83-91. doi: 10.1102/1470-7330.2010.9007. Review.

7.

Nuclear imaging of neuroendocrine tumours.

Sundin A, Garske U, Orlefors H.

Best Pract Res Clin Endocrinol Metab. 2007 Mar;21(1):69-85. Review.

PMID:
17382266
8.

Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.

Kaemmerer D, Peter L, Lupp A, Schulz S, Sänger J, Prasad V, Kulkarni H, Haugvik SP, Hommann M, Baum RP.

Eur J Nucl Med Mol Imaging. 2011 Sep;38(9):1659-68. doi: 10.1007/s00259-011-1846-5. Epub 2011 May 31.

PMID:
21626438
9.

Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.

Baumann T, Rottenburger C, Nicolas G, Wild D.

Best Pract Res Clin Endocrinol Metab. 2016 Jan;30(1):45-57. doi: 10.1016/j.beem.2016.01.003. Epub 2016 Jan 20. Review.

PMID:
26971843
10.

18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.

Balogova S, Talbot JN, Nataf V, Michaud L, Huchet V, Kerrou K, Montravers F.

Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):943-66. doi: 10.1007/s00259-013-2342-x. Epub 2013 Feb 16. Review.

11.

Pancreatic neuroendocrine neoplasms.

Hörsch D, Bert T, Schrader J, Hommann M, Kaemmerer D, Petrovitch A, Zaknun J, Baum RP.

Minerva Gastroenterol Dietol. 2012 Dec;58(4):401-26. Review.

PMID:
23207615
12.

Diagnostic imaging approach to gastro-entero-pancreatic carcinomas of neuroendocrine origin - single NET center experience in Poland.

Cwikla JB, Nasierowska-Guttmejer A, Jeziorski KG, Cichocki A, Zgliczynski W, Stepień K, Seklecka N, Durlik M, Malkowski B, Walecki J.

Neuro Endocrinol Lett. 2007 Dec;28(6):789-800.

PMID:
18063942
13.

Imaging of neuroendocrine gastro-entero-pancreatic tumours using radiolabelled somatostatin analogues.

Chiti A, van Graafeiland BJ, Savelli G, Ferrari L, Seregni E, Castellani MR, Bombardieri E.

Ital J Gastroenterol Hepatol. 1999 Oct;31 Suppl 2:S190-4.

PMID:
10604128
14.

Contribution of ¹¹¹In-pentetreotide SPECT/CT imaging to conventional somatostatin receptor scintigraphy in the detection of neuroendocrine tumours.

Sainz-Esteban A, Olmos R, González-Sagrado M, González ML, Ruiz MÁ, García-Talavera P, Gamazo C, Villanueva JG, Cobo A, de Luis D.

Nucl Med Commun. 2015 Mar;36(3):251-9. doi: 10.1097/MNM.0000000000000239.

PMID:
25369750
16.

Somatostatin receptor scintigraphy with 111In-pentetreotide in non-functioning gastroenteropancreatic neuroendocrine tumors.

Schillaci O, Spanu A, Scopinaro F, Falchi A, Corleto V, Danieli R, Marongiu P, Pisu N, Madeddu G, Delle Fave G, Madeddu G.

Int J Oncol. 2003 Dec;23(6):1687-95.

PMID:
14612942
17.

Nuclear medicine techniques for the imaging and treatment of neuroendocrine tumours.

Teunissen JJ, Kwekkeboom DJ, Valkema R, Krenning EP.

Endocr Relat Cancer. 2011 Oct 17;18 Suppl 1:S27-51. doi: 10.1530/ERC-10-0282. Print 2011 Oct. Review.

18.

Contemporary nuclear medicine imaging of neuroendocrine tumours.

Wong KK, Waterfield RT, Marzola MC, Scarsbrook AF, Chowdhury FU, Gross MD, Rubello D.

Clin Radiol. 2012 Nov;67(11):1035-50. doi: 10.1016/j.crad.2012.03.019. Epub 2012 May 23. Review.

PMID:
22633086
19.

Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals.

Bombardieri E, Coliva A, Maccauro M, Seregni E, Orunesu E, Chiti A, Lucignani G.

Q J Nucl Med Mol Imaging. 2010 Feb;54(1):3-15. Review.

20.

Nuclear imaging of neuroendocrine tumors with unknown primary: why, when and how?

Santhanam P, Chandramahanti S, Kroiss A, Yu R, Ruszniewski P, Kumar R, Taïeb D.

Eur J Nucl Med Mol Imaging. 2015 Jun;42(7):1144-55. doi: 10.1007/s00259-015-3027-4. Epub 2015 Mar 13. Review.

PMID:
25771906

Supplemental Content

Support Center